Company Information
CIN
Status
Date of Incorporation
22 August 1962
State / ROC
Mumbai / ROC Mumbai
Last Balance Sheet
31 March 2023
Last Annual Meeting
25 September 2023
Paid Up Capital
140,811,500
Authorised Capital
500,000,000
Directors
Anand Mahajan
Director/Designated Partner
about 2 years ago
about 2 years ago
Pabitrakumar Kalipada Bhattacharyya
Director/Designated Partner
about 2 years ago
about 2 years ago
Pranay Premchand Godha
Director/Designated Partner
about 2 years ago
about 2 years ago
Prafulbhai Anubhai Shah
Director
over 2 years ago
over 2 years ago
Priti Puri
Director/Designated Partner
over 2 years ago
over 2 years ago
Kinnera Murthy Bhagavatula
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Prakash Amrut Mody
Director/Designated Partner
almost 3 years ago
almost 3 years ago
Pradeep Bhandari
Nodal Officer
over 6 years ago
over 6 years ago
Prafull D Sheth
Director
about 22 years ago
about 22 years ago
Nasser Mukhtar Munjee
Director
over 22 years ago
over 22 years ago
Past Directors
Dilip Janardan Kunkolienkar
Whole Time Director
over 7 years ago
over 7 years ago
Neema Thakore
Company Secretary
over 10 years ago
over 10 years ago
Krishnan Subharaman
Company Secretary
almost 18 years ago
almost 18 years ago
Ramdas Maneklal Gandhi
Director
almost 41 years ago
almost 41 years ago
Patents
The present invention provides a process for the fermentative production and downstream purification of sodium hyaluronate of pharmaceutical grade and biomedical applications. The process includes bacterial fermentation with carbon sources like starch and sucrose to give Hyaluronic acid of high molecular weight. The...
The present invention provides a new crystalline R- form of imatinib mesylate which is characterized by rod shaped and XRD data. The invention also provides an efficient process for the preparation of the same. The said R- form is suitable for pharmaceutical formulations.
The present invention provides an improved process for preparation of phenylalkylaminoethylsalicylamide, an adrenergic receptor blocking agent from 5-chloroacetyl salicylamide intermediate. The present invention also provides process for preparation of 5-chloroacetyl salicylamide intermediate.
This invention relates to a process for the preparation and purification of a pure
crystalline Hydrochlorothiazide with overall purity 99.9% or greater and single impurity below 0.1%. This is a two-step process. In first step crude hydrochlorothiazide is prepared which is in second step purified to get highly pure ...
The present invention relates to the novel key intermediate, 4-{4-[(5S)-(Aminomethyl)-2-oxb-l,3-oxazolidin-3-yl]-phenyl}-morpholin-3-one perchlorate, in the synthesis of rivaroxaban. The invention further relates to the crystalline form of novel intermediate, the process to prepare the novel intermediate and method ...
The present invention provides an improved process for the preparation of pharmaceutically acceptable Sodium 2-propylpentanoate 2-propylpentanoic acid (1:1) or Divalproex sodium. Novelty of the process resides in single step synthesis of valproic acid. The invention provides less energy intensive,process to produce ...
The present invention relates to novel extended release solid oral dosage forms of paliperidone and methods for their manufacture thereof, useful for the treatment of Schizophrenia and Schizoaffective disorders.
The invention describes an improved, economical and scalable process for preparing 3-(3-trifluoromethylphenyl) propanol (compound II), which is a key intermediate for the synthesis of cinacalcet, its salts and/or solvates thereof.
The present invention relates to novel processes for the preparation of Ranolazine (I) and its acid addition salts and the novel process for the preparation of compound of formula (7).
Protein drug complex, pharmaceutical composition containing said proteins and methods for preparing the same. The invention is directed specifically to protein drug probiotic complex and oral therapy formulations. The said protein is preferably casein. Method for preparing said complex and oral formulation is disclo...
The present invention discloses a process of crystallization of insulin directly from the eluted fractions from reverse phase chromatography, in the presence of large quantity of organic solvent. The invention also discloses a method of drying of insulin crystals to obtain pharmacopoeial grade insulin, their composi...
The invention relates to an improved process for the preparation of candesartan cilexetil, particularly the deprotection of trityl candesartan cilexetil to obtain Candesartan cilexetil.
The present invention relates to a novel, cost effective process for the preparation of intermediates of valsartan and its further conversion into valsartan, having chiral purity above 99.8%.
The present invention is to provide an improved process for the preparation of tadalafil (I). The process according to present invention is operationally simple and suitable for industrial application which will avoid hazardous chemicals such as TFA, eliminate column chromatography and use of high boiling solvent li...
Abstract
The present invention relates to simple and cost effective process for production of pharmacopoeial grade Insulin Lispro. The precursor protein expressed as inclusion bodies during fermentation of recombinant bacterial cells was isolated, chemically treated, partially purified, refolded and enzymatically c...
The present invention relates to the simple and cost effective process for preparation of pharmacopoeial grade Insulin Glargine from a bacterial fermentation process followed by isolation of IBs, refolding, enzymatic conversion and chromatographic purification. Pure Insulin Glargine is lyophilized or crystallized to...
The present invention relates to an improved process for preparation of 4-(4'-chlorophenyl)-1H-2,3-benzoxazin-l-one intermediate useful for preparation of Chlorthalidone.
The present invention refers to novel process for the preparation of Apixaban. Further, the invention also related to a process for the preparation of intermediate of Apixaban from very basic and cheap row material i.e. Aniline which is widely commercially available. The present invention provides process for prepar...
The present invention relates to an improved, environmentally friendly process for the .preparation of pharmaceutically acceptable acid addition salts of Dronedarone starting from 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitro-benzofuran in a single organic .solvent . system! The process according to present invention is o...
The present invention relates to Orally Disintegrating Tablets (ODT) of Tofacitinib and its pharmaceutical^ acceptable salts and the process to produce the ODT. The invention further relates to ODTs comprising Tofacitinib and its pharmaceutically acceptable salts, at least one sweetening agent, at least one disinteg...
The present invention refers to an improved process for the preparation of Apixaban. Further, the invention also related to a process for the preparation of intermediate of Apixaban from very basic and cheap row material i.e. Aniline which is widely commercially available. The present invention provides process for ...
The invention relates to an improved process for the large scale production of chiral Rivastigmine, or its pharmaceutically acceptable salts, that possesses cholinesterase inhibitor activity and is useful in the treatment of Alzheimer"s disease.
The present invention relates to an improved one-pot process for the preparation of pure Buspirone base. The said process involves the step of condensation of 1-(2-pyrimidinyl)-piperazine, 1,4-dibromobutane and 3,3-tetramethylene glutarimide in presence of an inorganic base and in an organic solvent.
...
The present invention relates to the pharmaceutical compositions of esomeprazole. The present invention relates to a gastric resistant multiple unit esomeprazole swallowable dosage form comprising of enteric coated pellets and process for their manufacture thereof.
The present invention discloses a process of crystallization of insulin Lispro directly from the eluted fractions from reverse phase chromatography, in the presence of organic solvent. The invention also discloses a method of drying of insulin crystals to obtain pharmacopoeial grade insulin, their compositions and a...
The present invention relates to a one pot process for the preparation of Teriflunomide of formula (I). Teriflunomide is produced without isolation of Leflunomide of formula (II). Substantially lesser quantities of chlorinating agent is used to prepare acid chloride of the formula (IV).
The present invention relates to the high yielding process of recombinant expression of insulin and insulin analogues in insoluble forms by fermentation of recombinant E. coli BL21 DE3 Gold cells containing plasmid pET 28a, in a fermentation medium at 37°C temperature with specific feeding rates. The novelty and inv...
The present invention describes an improved process for the synthesis of 4"-[(l,4"-dimethyl-2"-propyl [2,6"-bi-1H-benzimidazol]-1"-yl)methyl]-[ 1,1"-biphenyl]-2-carboxylic acid, that is Telmisartan.
The present invention provides process for the preparation of crystalline forms of Lornoxicam, herein designated as Form I and Form II.
The present invention provides a single pot process for the preparation of 5-methyl-N~[2-(4-sulfamoylphenyl)ethyl]pyrazine-2-carboxamide for use in the synthesis of Glipizide. The invention also relates to process for preparation of pure Glipizide with improved yield.
The present invention relates to an improved process for the preparation of Dronedarone and its pharmaceutically acceptable salts. The said process involves the steps of Friedel-Craft acylation of 2-n-butyl-5-nitrobenzofuran with p-anisoyl chloride in presence of Lewis acid to form 2-n-butyl 3-(4-methoxy-benzoyl) 5-...
ABSTRACT
The present invention relates to a bilayer solid oral tablet composition and its process comprising beta-blocker and angiotensin II antagonist useful in the treatment of hypertension. The present invention also relates to the use of hydrophilic and hydrophobic polymers in pharmaceutical composition as reta...
The present invention relates to a novel and improved deprotection process of trityl sartans for the preparation of sartans, more particularly for the synthesis of candesartan cilexetil and olmesartan medoxomil in presence of chlorinated protecting group such as
trimethyl silyl chloride (TMSC1)
...
The present invention is related to an improved and efficient process for preparation of (3R,4R)-(l-benzyl-4-methylpiperidin-3-yl)-methylamine which comprises: (a) N-acylation of 3-Amino-4-methyl pyridine; (b) Quarternization of 3-AcetyIamino-4-methyI pyridine using benzyl halide; (c) Partial reduction of quartemize...
The present invention relates to an effervescent stable pharmaceutical composition of omeprazole. The present invention describes about stable, pseudo dose proportional, solid oral pharmaceutical composition of omeprazole in the form effervescent tablets It also describes novel method of manufacturing of stable soli...
The present invention relates to an improved high yields and high throughput process for the preparation of 4-(l-Hydroxy-1-methyl ethyl)-2-propyl-l-[[2"-(lH-tetrazol-5-yl)[l,l"-biphenyl]-4-yl)methyl]-l-H-imidazole-5-carboxylic acid (5-methyl-2-oxo-l, 3-dioxol-4-yl) methyl ester, known as Olmesartan medoxomil which c...
The present invention relates to a novel and one pot process for the preparation of bis(3-methyl-2-thienyl)methanone an important intermediate needed for the synthesis of a potent anticonvulsant drug tiagabine hydrochloride from 2-bromo-3-methyl thiophene.
The invention discloses an improved process for the preparation of 2-[(2- aminoethoxy) methyl]-4-(2-chlorophenyl)1,4-dihydro-6-methyl-3,5-pyridine dicarboxylic acid-3ethyl 5-methyl ester of formula (I) and pharmaceutically acceptable acid salts by reacting phthloyl amlodipine with methyl amine solution to get the pa...
The present invention provides a novel one-pot process for preparation of Pantoprazole sodium sesquihydrate Form-I in the pure form without isolating the pantoprazole base.
Crystalline form of Telemisartan and the process for its manufacturing. The present invention discloses a process for the preparation of novel crystalline form of 4"-[2-n-propyl-4-methyl-6-(1-methylbenzimid-azole-2-yl)benzimidazole-1-ylmethyl]biphenyl-2-carboxylic acid (Telmisartan) (Formula-I).
...
A process for the preparation of 7-hydroxy-3,4-dihydro carbostyril (II) by intramolecular Fridel-Craft alkylation of N-(3-methoxyphenyl)-3-chloropropionamide (I) in which an equivalent of N-(3-methoxyphenyl)-3-chloropropionamide (I) is contacted with a Lewis acid (e.g. aluminium chloride) in dimethyl acetamide (DMA)...
The present invention relates to a process for preparation of a pharmaceutical composition containing anti-diabetic substance such as metformin or its pharmaceutically effective salts or pro-drug as modified release either singly or in combination with other drugs and the process of the preparation for the same. The...
The invention relates to commercially viable process for the preparation of Rosuvastatin by an early introduction of correct absolute stereochemistry at C-5 (S) of Rosuvastatin side chain followed by regioselective chain extension using novel side chain building blocks and less expensive reagents. it is yet another...
The present invention relates to an improved process for the preparation of dibenzo[b,f][1,4]thiazepine-11-[10H]-one, a key intermediate in the synthesis of Quetiapine. The process of present invention comprises the steps of reaction of o-halonitrobenzene with thtiophenol; followed by in-situ reduction; reaction of ...
The present invention relates to a process for the preparation of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2, 3-dihydro-1H-pyrrolizin-5-yl acetic acid, in which the key intermediate, 5-Benzyl-3,3-dimethyl-3,4-dihydro-2H-pyrrole is obtained by the hydrogenation of 2,2-dimethyl-4-oxo-5-phenyl-nitropentane. The inventi...
The present invention relates to a novel process for the purification of olmesartan medoxomil. The process according to present invention comprises the steps of detritylation of trityl olmesartan; extraction of olmesartan medoxomil and purification via pH adjustment with a base.
The present invention relates to an improved process for the manufacture of Losartan potassium. The process comprises of condensation of 2-butyl-4-chloro-5-formyl imidazole with 2-cyano-4-bromomethyl biphenyl in a biphasic solvent system under phase transfer catalysis followed by insitu reduction using sodium borohy...
The present invention relates to the improved, scalable and efficient manufacturing procedure for the preparation of the antidepressant Cis(IS)-N-methyl-4-(3,4-Dichloropenyl)-1,2,3,4-tetrahydro-1-napthaleneamine hydrochloride, Sertraline Hydrochloride polymorphic form II. The present invention further relates to the...
The present invention relates to controlled/ extended release for human oral pharmaceutical compositions containing Terbinafine and or its salts that release the active ingredient over an extended period of time and this pharmaceutical composition can be a sustained release oral dosage form that release the drug in ...
An improved process for the preparation of 11-(4-[2-(2-hydroxyethoxy)ethyl]-l-piperazinyl)-dibenzo[b,f][l,4]thiazepine, known as Quetiapine and its hemifumarate salt, comprising chlorination of Dibenzo[b,f][l,4]thiazepine-11(10H)-one in presence of pyridine or substituted pyridine as a base to give 11-chloro-dibenzo...
Novel and highly efficient process for preparing Human Insulin from Human Insulin Precursor is disclosed. Process comprises treating the Human Pro-insulin prepared from Human Insulin Precursor with Trypsin, separating the closely related impurity Des-Thr (B30) Insulin from the reaction mixture using simple ion excha...
The present invention relates to the field of pharmaceutical technology and describes a novel and advantageous method of manufacturing of extended release oral pharmaceutical composition comprising Alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof. This pharmaceutical compositio...
The present invention relates to extended release oral pharmaceutical composition comprising Alfuzosin or pharmaceutically acceptable salt, solvate, enantiomers or mixture thereof. This pharmaceutical composition can be an extended release floating system or dosage form containing Alfuzosin and or its salt and the f...
The present invention relates to the field of pharmaceutical technology and describes the stabilized zolmitripitan pharmaceutical composition in the form of orodispersible tablets prepared by direct compression technique, using croscarmellose sodium in stabilizing effective amount. This composition is for the oral a...
Improved method for the synthesis of an Antihypertensive reagent like Alfuzosin is described. This process includes the synthesis of novel intermediates like substituted urea derivative and guanidines as well as the cyclized guanidine viz. (±)-N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro...
The present invention relates to an improved process for the preparation 1-aminoadamantanes and acid addition salts thereof. In particular, it relates to an improved process for the preparation of memantine hydrochloride. The present invention further provides an improved process for the preparation of intermediates...
The present invention relates to the field of pharmaceutical technology and describes about stable pharmaceutical composition, simple and cost effective novel methods of manufacturing of immediate release solid oral dosage forms comprising tiagabine or its pharmaceutically acceptable salts, solvates, enantiotners or...
The invention relates to commercially viable process for the preparation of Rosuvastatin by an early introduction of the correct absolute stereochemistry at C-5 (s) of Rosuvastatin side chain followed by regioselective chain extension using novel side chain building blocks. It is yet another object of the invention ...
This invention relates to a manufacturing process for the preparation of bisoprolol and its pharmaceutically acceptable salt as well as its intermediates. The intermediate 4-[(2-isopropoxyethoxy)methyl]phenol is prepared by reaction of 4-hydroxybenzyl alcohol with 2-isopropoxy ethanol in presence of Amberlyst 15 in ...
Process for the preparation of Sertraline hydrochloride form-II:
Formula-I
The present invention discloses a process for the preparation of Sertraline hydrochloride form-11. The form-II of Sertraline hydrochloride, which is cis- (IS, 4S)-N-methyl-4- (3,4-dichlorophenyl)-! ,2,3,4-tetrahydro-l-naphthalenamine hydroc...
This invention discloses a process for the preparation of 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine of a formula (I), commonly known as Lamotrigine which comprises the step of reacting aminoguanidine bicarbonate and 2,3-dichlorobenzcynide with a reagent prepared by dissolving phosphorus pentoxide and methane...
This invention describes a process for the preparation of N-(4-trifluoromethyl)-5-methylisoxazole-4-carboxamide commonly known as leflunomide comprising : (a) reacting ethylacetoacetate, triethylorthoformate, and acetic anhydride with simultaneous distillation to form ethyl ethoxymethyleneacetoacetic ester; (b) reac...
A process of extracting recombinant protein from inclusion bodies extracted from the E.coli comprising the step of: - solubilizing recombinant proteins expressed in the said E.coli with a buffer having a pH in the range of 7 to 11, wherein the said buffer contains guanidine hydrochloride, organic solvent and water, ...
This present invention relates to a novel pharmaceutical composition containing a combination of a NSAID and an anti-spasmodic drug, useful for the treatment of muscle spasms and associated pain, soreness and tightness of muscles in mammalian organism, comprising therapeutically effective amount of, (i) delayed rele...
The present invention provides a method for preparing a recombinant lectin expressed in E.coli. This method comprises the synthesis of a lectin gene sequence derived from the MADI MS/MS and X-ray crystallographic data of the Sclerotium rolfsii lectin, a soil borne phytopathogenic fungus, and its cloning in E.coli.
...
2-Halo-4-aminoquinazolines are produced by a one-step process involving intramolecular cyclization of appropriately substituted formamide derivatives in the presence of
phosphorous oxyhalides. Exemplary of the process is the intramolecular cyclization of
3,4-dimethoxy-6-cyanoaniline-l-yl formamide in the presence ...
A process for the preparation of 1-cyano-[(4-methoxyphenyl)methyl] cyclohexanol by reacting cyclohexanone with the carbanion of 4-methoxyphenyl acetonitrile in the presence of polyethylene glycol-400 (PEG-400) or Aliquate-336, as a phase transfer catalyst (PTC). The present invention also relates to an novel proces...
The present invention relates to pharmaceutical composition containing anti-diabetic substance such as metformin or its pharmaceutically effective salts or pro-drug as modified release either singly or in combination with drugs and the process of the prepration for the same. The composition comprises of anti-diabeti...
The present invention relates to the field of pharmaceutical technology and describes improved methods of manufacturing of stable pharmaceutical composition comprising Pramipexole or its pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof. In particular, the invention is directed to manufactur...
The present invention describesan improved and scalable process for the preparation of terahydro-N-[3-(methylamino)propyl]-2-furan carboxamide an important intermediate needed for the synthesis of an antihypertensive drug alfuzosin.
The present invention relates to an improved process for preparation of an antihypertensive agent, (S)-N-( 1 -carboxy-2-methyl-prop- 1 -yl)-N-pentanoyl-N-[2 ‘(1 Htetrazole-5-yl)-biphenylj-4-ylmethylj -amine, (valsartan), which comprises, selective reaction of 4-bromomethyl-2’ -(1 -triphenylmethyltetrazol-5-yl)biphen...
The present invention relates to an improved process for the preparation of eszopiclone comprising the steps of condensation of 6-(5-chloropyrid-2-yl)-5-hydroxy-7-oxo-5.6-dihydropyrrolo[3,4-b]pyrazine with l-chlorocarbonyl-4-methylpiperazine hydrochloride and then resolution of obtained racemic Zopiclone using D-(+)...
The present invention reveals a new process for the efficient folding of S- sulphonated recombinant human insulin precursor wherein the folding mixture consists of the insulin precursor protein as sulphonates and uses denaturant, reductant, organic solvent, additives and a buffer.
A PROCESS FOR PREPARATION OF A PHARMACEUTICAL COMPOSITION CONTAINING CYCLOOXEGENASE INHIBITOR SUBSTANCE FOR ORAL USE
The present invention relates to a preparation of a pharmaceutical composition containing cyclooxegenase inhibitor substance such as meloxicam.The drug is suspended in a suspension base comprising o...
The present invention describes an improved and economic process for the synthesis of
6-chloro-4-hydroxy-2-methyl-3-(2-pyridylcarbamoyl)2H-thieno[2,3-e]-l,2-thiazine-l,l-dioxide,
Lornoxicam.
The present invention provides an improved process for the preparation of Ivabradine intermediate, (S)-7,8-Dimethoxy -3-{3-{N [(4,5-dimethoxybenzocyclobut-l-yl) methyl] -N- (methyl) amino} propyl}-1,3- dihydro-2H- 3-benzazepin -2- one of formula-IV, its oxalate salt of formula DC, and Ivabradine free base of formula...
The present invention relates to the field of pharmaceutical technology and describes novel methods of manufacturing of stable pharmaceutical composition comprising Memantine or its pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof. In particular the invention is directed to manufacture mema...
The present invention relates to an improved process for the racemization of (R)-3-
(dimeth);lamino)-1-(2-thienyl)-l-propanol, an undesired enantiomer formed during
synthesis of duloxetine hydrochloride, using an aqueous organic acid. The process
according to present invention is safe, eco-friendly, high yieldi...
The present invention discloses a water-soluble protein based pharmaceutical composition and a process for the preparation of the same comprising of the steps of solubilising a carrier protein in a suitable buffer, adding the dissolved pharmaceutical agent/s to the solubilised carrier protein and stirring at a defin...
The present invention relates to the field of pharmaceutical technology and describes about extended release pharmaceutical composition which is simple and cost effective. It also provides methods of manufacturing of extended release solid oral dosage forms comprising nifedipine. This composition taken orally in the...
The present invention provides an environment friendly process for making Losartan Potassium. According to the present invention, to the Losartan free acid, aqueous potassi um hydroxide solution is added. The mixture is stirred, and the filtrate is added to the water immiscible solvent. The water was removed azeotro...
The present invention provides an improved process for preparation of pure intermediates, of Ivabradine hydrochloride, of formula-V, formula-II and the novel intermediate, S (+)- N- [(4,5-Dimethoxybenzocyclobut-l-yl)methyl]-N-(methyl)amine mandelic acid salt of formula Il-a.
The present invention relates to a immediate release stable pharmaceutical composition containing Atomoxetine or a pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof and its method of preparation suitable for oral administration for the treatment of symptoms of Attention Deficit Hyperactivity...
The prsent invention relates to a process for the preparation of N-(trans-4-isopropyl cyclohexylcarbonyl)-D-phenylalanine commonly known as Nateglinide of general formula (I) and its intermediates. Also provided is a process for the preparation of chirally pure Nateglinide substantially in Form-B.
...
The present invention relates to the field of pharmaceutical technology and describes methods of manufacturing of stable, modified release, solid oral pharmaceutical composition comprising. memantine or its pharmaceutically acceptable salt, solvate, enantiomers or mixtures thereof. In particular the invention is dir...
The present invention relates to an improved process for the preparation of Darifenacin and salts thereof. The said process involves the steps of selective N-alkylation of the 3-(S)-(+) - (1-carbamoyl-l, 1-diphenyl methyl)-pyrrolidine L-(+) tartrate with 5-(2-bromoethyl)-2, 3-dihydrobenzofuran in presence of base, s...
The present invention discloses genes for new variants in E.coli that are more close to the wild type lectin sequence but still differ in surface charges. This recombinant version (exemplified Rec-2 and Rec-3) are cancer cell binding with anti tumor activity show blood group specificity similar to the native lectin ...
The invention relates to an improved process for the preparation of (+)-6-carboxamido-3-N-methylamino-l,2,3,4-tetrahydrocarbazole, known as Frovatriptan, having activity as 5HT1 receptor agonists and isolation of the novel intermediate thereof with high yields and purity.
The present invention relates to a process for the preparation of Ezetimibe via a novel intermediate. Trans-3(R)-(3-[2-oxo-4(s)-(4-benzyloxyphenyl)-1-(4-fluorophenyl)-azetidinyl]propanoic acid is converted to trans-N-methoxy-N-methyl-3(R)-3-[2-oxo-4(S)-(4-benzyloxyphenyl)-1-(4-fluorophenyl)-azetidinyl]propanamide an...
The present invention provides a novel crystalline polymorph of the psychotropic drug aripiprazole and a process for its preparation.
Derivatives of anacardic acid having antimicrobial properties and method for preparing said derivatives. The antimicrobial properties properties include bacteriostatic and bacteriocidal activity.
The present invention describes an improved process for the synthesis of Dimethyl Fumarate comprising reaction between Fumaric acid and aqueous hydrochloric acid in methanol at suitable temperature to obtain the crude product followed by purification of crude product with suitable solvent to obtain pure dimethyl fum...
The present invention is related to an improved process for the preparation of Dabigatran etexilate mesylate of Formula-!. The process according to present invention is operationally simple and suitable for industrial application which will avoid hazardous chemicals and eliminate column chromatography to get ICH qua...
The present invention is related to novel intermediate compounds of formula (4) and (10), methods for their preparation and a method for preparation of Teneligliptin using theses novel intermediates.
wherein X is halogen, -S(=0)2Ri, -Si (R2H aryl or substituted aryl, R] is C1-C4 alkyl group and R2 is C1-C4 alkyl ...
The present invention is related to novel intermediates (1), (la) and (2) and process to produced thereof and novel process for the preparation of piperazine derivatives (3) and (3a). These are useful for the preparation of certain DPP-fV inhibitors and to prepare compounds useful for the treatment of HIV and AIDS w...
The present invention provides an improved process for the synthesis of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyJ-9-hydroxy-4H-pyrido[l,2-a]pyrimidine-4-one (CMHTP), an intermediate in the synthesis of Paliperidone and also a method for the synthesis of pure Paliperidone.
The present invention relates to the field of pharmaceutical technology and describes prolonged release oral pharmaceutical matrix type of composition comprising clarithromycin or its pharmaceutically acceptable salt solvate, enanliomers or mixtures thereof & method for manufacturing of the said composition. This co...
The present invention relates to an improved process for the preparation of Azilsartan medoxomil (1) or pharmaceutically acceptable salts with high purity and good yield on commercial scale.
The present invention provides processes for the preparation of novel intermediates of Ranolazine, such as [(2,6-dimethyl phenyl) amino carbonyl methyl]-4-carbethoxy piperazine of formula (IV), l-[3-(2-Methoxy phenoxy)-2-hydroxy propyl]-4-carbethoxy piperazine of formula (VI) and the use of these novel intermediates...
The present invention relates to a process for preparation of Cinacalcet hydrochloride and to the process for preparation of intermediate thereof.
The present invention relates to pharmaceutical composition containing cyclooxegenase inhibitor substance such as meloxicam and the process of the preparation for the same. The drug is suspended in a suspension base comprising of carbopol, parabens, water and other fillers and other additives to formulate a stable p...
ABSTRACT
The present invention is related to an improved process for the preparation and purification of crystalline polymorph of Vortioxetine hydrobromide of Formula-I and Vortioxetine hydrochloride of Formula-la. The process according to present invention is operationally simple and suitable for industrial applic...
A modified lectin protein is provided having at least one amino acid modification in an amino acid sequence of SEQ ID NO. 1 orin an amino acid sequence having at least 60% homologythereto. The amino acid modification is selected from one of more of the following: at least one amino acid modification in a carbohydrat...
The present invention relates to a stable, reproducible and bioequivalent
pharmaceutical composition comprising Apixaban having D90 more than 100 u, more
preferably more than 300p-t0 1000p and most preferably more than 350}; to 800p and
one or more pharmaceutically acceptable excipient, a wet granulation process ...
The present invention relates to a stable, reproducible, binderfree and bioequivalent pharmaceutical composition comprising Apixaban having D90 more than 100 [i, more preferably more than 300u, to lOOOu and most preferably more than 350\i to 800u. and one or more pharmaceutically acceptable excipient. A process for ...
The invention relates to Vortioxetine Hydrobromide having particle size distribution
of D98 105—13511, D50 35—60}; and D5 7-10p as well as to a stable, reproducible and
bioequivalent pharmaceutical composition comprising Vortioxetine Hydrobromide
having particle size distribution of D98 105-13511, D50 35-6011 and...
ABSTRACT:
The present invention relates to crystalline solid form of sacubitril, sacubitril sodium and process for the preparation thereof.
The present invention relates to an extended release pharmaceutical composition of Paliperidone or its pharmaceutically acceptable salt, solvate, enantiomers or mixtures and methods for their manufacture thereof, useful for the treatment of Schizophrenia and Schizoaffective disorders which provides initial slow rate...
The present invention relates to an improved process for the synthesis of (R)-Lacosamide in which free base of O-methyl-N-benzyl-D-Serinamide is not isolated before acylation. The process avoids the use of column chromatography and chiral resolution for the preparation of different stages of Lacosamide.
...
The present invention relates to resinates of Tofacitinib. The invention also relates to taste masked, stable and readily dispersible resinates of Tofacitinib, rapidly disintegrating and or quick release taste masked pharmaceutical compositions comprising the said resinates and process for the preparation of resinat...
The present invention relates to enzymatic reduction of 3-quinuclidinone to (R)-3-quinuclidinol (Scheme I), by reacting 3-quinuclidinone with a variant of ketoreductase enzyme derived from Rhodotorula rubra. The invention also relates to enzymatically produced (R)-3-quinuclidinol wherein the substrate loadi...
An alternative and improved process for the preparation of Apremilast (Formula I) and Apremilast form B or a pharmaceutically acceptable salt thereof is provided. The novel process includes hydrogenation in acetone, Cyclization and acetylation followed by condensation in methyl isobutyl ketone (MIBK) and acetic acid...
ABSTRACT
PHARMACEUTICAL COMPOSITIONS OF APREMILAST
The present invention relates to a disintegrant free pharmaceutical composition comprising apremilast or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. Particularly the present invention relates to disintegran...
The present invention relates to an enzymatic process for the preparation of (R)-Sitagliptin. The process involves reductive animation of Pro-Sitagliptin to (R)-Sitagliptin using novel transaminase enzymes. The invention also relates to the Nucleotide sequences encoding novel transaminase enzymes and process to pr...
ABSTRACT:
Novel crystalline polymorphic form of Selexipag compound of formula-I and process for preparation thereof. The invention also provides a process for preparation of amorphous form of Selexipag compound of formula-I.
The invention relates to vortioxetine hydrobromide having particle size distribution of D98 100-200m D50 35-90^ and D5 7-30\i as well as to a stable, reproducible and bioequivalent pharmaceutical composition comprising vortioxetine hydrobromide having particle size distribution of D98 100-200^, D50 35-90^ and D5 7-3...
The present invention relates to the leader sequence for higher expression of recombinant proteins. The invention further relates to the process for preparation of insulin and insulin analogues using leader sequence. The leader peptides significantly increases the expression of pre-proinsulin. The invention also rel...
The present invention relates to the protein for treatment of inflammatory diseases. In particular the invention relates to a lectin for use in the treatment, reduction in progression and curing of inflammation in a subject in need thereof. Pharmaceutical compositions comprising said lectin are also described. The l...
The present invention relates to a novel process for the preparation of filgotinib or a pharmaceutically acceptable salt and intermediates thereof which avoid Suzuki coupling reaction.
The present disclosure provides an extended release composition of tofacitinib for oral administration, and methods of making the composition. The extended release composition employs a matrix drug core comprising tofacitinib or a pharmaceutically acceptable salt thereof and at least one release controlling polymer....
The present invention relates to the process to prepare recombinant lectin having amino acid sequence of SEQ ID NO:l, wherein the process comprises fed-batch fermentation of a clone in a host cell at specific feeding rate with Carbon to Nitrogen ratio of 3:1 to 6:1. The invention also relates to the process of purif...
ABSTRACT
The present invention relates to stable formulations of recombinant proteins. The invention specifically relates to the formulations of recombinant lectins derived from Sclerotium rolfsii lectin. The formulation comprises recombinant lectin derived from Sclerotium rolfsii lectin and a pharmaceutically acce...
A recombinant lectin for use in a method of treatment of cancer by inhibiting angiogenesis in a subject. The treatment comprises administration of a therapeutically effective amount of the recombinant lectin.
Abstract
The present invention relates to the combination chemotherapy with recombinant lectin protein. The invention specifically relates to the cytotoxic effect of recombinant lectin protein having amino acid sequence of SEQ ID NO: 1 standalone and in combination with other therapeutic agents, wherein the other t...
The invention relates to a pharmaceutical composition comprising cinacalcet or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipient. The invention also relates to the pharmaceutical composition comprising cinacalcet or pharmaceutically acceptable salts thereof having a part...
ABSTRACT
The present invention is relates to a process for the preparation of opicapone and a process to prepare intermediates to be used therein.
ABSTRACT
The present invention relates to a stable, reproducible and bioequivalent pharmaceutical composition comprising Apixaban having D90 more than 100 µ, more preferably more than 300µ to 1000µ and most preferably more than 350µ to 800µ and one or more pharmaceutically acceptable excipients, such as but not l...
The present invention relates to nucleotide sequence of SEQ ID 1 and SEQ ID 2 encoding recombinant 3-Quinuclidinone reductase and Glucose Dehydrogenase respectively. The invention further relates to the clone comprising the said nucleotide sequences and process to prepare 3-Quinuclidinone reductase and Glucose Dehyd...
The invention provides a compound of formula (I)
or a pharmaceutically acceptable salt thereof;
wherein Q is a group of formula Q1 or Q2;
(wavy bond) represents the points of attachment;
wherein R1 is –NRaRb;
R2 is hydrogen or a C1-C10 alkyl group;
Ra and Rb independently represent hydrogen o...
LECTIN PROTEIN FOR TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES
Abstract
The present invention relates to the lectin protein for the treatment and prevention of neurodegenerative diseases. The invention further relates to the recombinant lectin protein is derived from Sclerotium rolfsii lectin having seq...
The present invention relates to recombinant proteins, compositions and methods of stabilization thereof. The invention specifically relates to the stable recombinant protein of SEQ ID NO: 1 and composition comprising recombinant protein of SEQ ID NO: 1. The invention further relates to method of preparing, storing ...
The present disclosure relates to protein-drug conjugates. The present disclosure specifically relates to the protein-drug conjugates, wherein the protein is a lectin protein having amino acid sequence of SEQ ID NO: 1; or lectin protein having at least 70% sequence identity to SEQ ID NO: 1. The disclosure further re...
The present disclosure provides a modified protein sequence i.e., recombinantly expressed glycan binding protein. The said glycan binding protein is a variant of Sclerotium Rolfsii Lectin and is modified to include attributes like enhanced molecule stability, reduced N-terminal methionine impurities and aid in conju...
The present invention relates to the pharmaceutical compositions of lectin proteins and its use for the prevention, treatment and cure of inflammation, including inflammatory disease. The invention specifically relates to the pharmaceutical compositions for topical application comprising lectin proteins and its use ...
The present invention relates to the protein for treatment of infectious disease caused by Coronaviridae. In particular, the invention relates to a recombinant Sclerotium rolfsii lectin for use in the treatment, reduction in progression and curing of SARS-COV2disease in a subject in need thereof. Pharmaceutical comp...
The present invention relates to a recombinant plasmid, methods and compositions for the expression of recombinant proteins with minimal N-terminal initiator methionine. The present invention also provides strategies for efficient removal of N-terminal initiator methionine in recombinant proteins expressed at indust...
ABSTRACT
“PROCESS FOR THE PREPARATION OF NINTEDANIB; AN INTERMEDIATE AND/OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF”
The present invention provides a process for the preparation of Nintedanib and/or its pharmaceutically acceptable salts. Furthermore, it provides novel intermediate and process for preparing th...
ABSTRACT
“AN IMPROVED METHOD FOR MANUFACTURING OF AN INTERMEDIATE, DIBENZO [B, F] [1,4] THIAZEPINE-11 (10H)-ONE, OF QUETIAPINE”
The present invention provides an improved method for manufacturing of Dibenzo[b,f][1,4]thiazepine-11(10H)-one which is used in the synthesis of quetiapine API. Said method is carried o...
Registered Trademarks
[Class : 5] Medicinal And Pharmaceutical Preparations, Multivitamins And Dietary Supplements
Renewal of trademark is due. Renewal request in prescribed form is to be filed by the applicant.
[Class : 5] Medicinal And Pharmaceutical Preparations, Multivitamins And Dietary Supplements
Renewal of trademark is due. Renewal request in prescribed form is to be filed by the applicant.
[Class : 5] Medicinal And Pharmaceutical Preparations, Multivitamins And Dietary
Supplements
Renewal of trademark is due. Renewal request in prescribed form is to be filed by the applicant.
View +124 more Brands for Unichem Laboratories Limited.
Charges
31 May 2019
Kotak Mahindra Bank Limited
125 Crore
23 January 2018
Citi Bank N.a.
269 Crore
16 July 2016
Bank Of India
21 Crore
26 November 2014
Biotechnology Industry Research Assistance Council
80 Lak
27 August 1988
Bank Of Baroda
50 Lak
05 September 1988
Bank Of Baroda
50 Lak
18 November 1966
The Bank Of India
1 Lak
27 May 1963
Bank Of India
15 Lak
17 May 1995
Bank Of India
10 Crore
27 March 1988
Bank Of India
50 Lak
23 February 1999
Bank Of India
25 Crore
19 November 2002
Bank Of India
37 Crore
14 January 2000
Bank Of India
25 Crore
17 March 1992
I.d.b.i.
1 Crore
27 December 1973
Uttar Pradesh Finacial Corp.
3 Lak
27 October 1969
Uttar Pradesh Financial Corp.
7 Lak
12 April 1991
The Mitsui Taiyo Kobe Bank Ltd.
1 Crore
13 January 1990
The Mitsui Bank Ltd.
1 Crore
01 October 1991
The Mitsui Taiyo Kobe Bank Ltd.
1 Crore
03 November 1970
Unichem Laboratories Ltd.
3 Lak
24 May 2000
Birla Sunlife Asset Management Co. Ltd.
10 Crore
18 November 2002
Cooperative Centrale Raiffeisen Boerenle Enbank B.a.
13 Crore
18 November 2002
Bank Of India
0
28 August 2000
Icici Limited
15 Crore
07 March 1994
Bank Of Baroda
12 Lak
12 June 1986
Bank Of Baroda
25 Lak
26 December 1986
Bank Of India
80 Lak
01 June 1990
Bank Of Baroda
2 Crore
27 September 1988
Bank Of India
50 Lak
09 October 1989
Bank Of India
1 Crore
03 July 1991
Bank Of India
3 Lak
31 July 1987
Bank Of India
50 Lak
05 March 1987
Bank Of India
3 Lak
17 June 1986
The Skura Bank Ltd.
30 Lak
27 July 1974
Bank Of India
13 Lak
03 February 1982
The State Indutrial & Investment Corp. Of Mahrashtra Ltd.
60 Lak
01 October 1976
The State Industrial Invest. Corp. Of Mahrashtra Ltd.
20 Lak
02 April 1980
The State Indus. Invest. Corp. Of Maharashtra Ltd.
20 Lak
26 December 1977
Bank Of India
1 Crore
12 May 1980
Bank Of India
30 Lak
23 March 1999
Industrial Development Bank Of Indiat
10 Crore
19 February 1999
Industrial Development Bank Of India
12 Crore
15 December 1997
Sicom Limited
10 Crore
01 March 1985
The Industrial Credit And Invest. Corp. Of Inida Limited
1 Crore
26 April 1988
The Army Group Insurance Fund
1 Crore
22 May 1997
Bank Of Baroda
2 Crore
18 June 1997
The Sakura Bank Limited
3 Crore
15 April 1991
The Industrial Credit And Invest. Corp. Of Inida Limited
1 Crore
13 July 1994
The Sakura Bank Ltd.
60 Lak
21 November 1980
Life Insurance Corp. Of India
25 Lak
28 February 2020
Axis Bank Limited
30 Crore
31 May 2019
Others
0
28 February 2020
Axis Bank Limited
0
04 January 2022
Others
0
16 July 2016
Bank Of India
0
23 January 2018
Citi Bank N.a.
0
01 June 1990
Bank Of Baroda
0
24 May 2000
Birla Sunlife Asset Management Co. Ltd.
0
14 January 2000
Bank Of India
0
15 December 1997
Sicom Limited
0
26 April 1988
The Army Group Insurance Fund
0
27 December 1973
Uttar Pradesh Finacial Corp.
0
03 November 1970
Unichem Laboratories Ltd.
0
27 October 1969
Uttar Pradesh Financial Corp.
0
02 April 1980
The State Indus. Invest. Corp. Of Maharashtra Ltd.
0
23 March 1999
Industrial Development Bank Of Indiat
0
23 February 1999
Bank Of India
0
19 February 1999
Industrial Development Bank Of India
0
18 June 1997
The Sakura Bank Limited
0
07 March 1994
Bank Of Baroda
0
01 October 1991
The Mitsui Taiyo Kobe Bank Ltd.
0
03 July 1991
Bank Of India
0
12 April 1991
The Mitsui Taiyo Kobe Bank Ltd.
0
19 November 2002
Bank Of India
0
13 January 1990
The Mitsui Bank Ltd.
0
27 September 1988
Bank Of India
0
12 May 1980
Bank Of India
0
21 November 1980
Life Insurance Corp. Of India
0
26 December 1986
Bank Of India
0
05 March 1987
Bank Of India
0
31 July 1987
Bank Of India
0
27 August 1988
Bank Of Baroda
0
05 September 1988
Bank Of Baroda
0
15 April 1991
The Industrial Credit And Invest. Corp. Of Inida Limited
0
26 November 2014
Biotechnology Industry Research Assistance Council
0
22 May 1997
Bank Of Baroda
0
13 July 1994
The Sakura Bank Ltd.
0
01 October 1976
The State Industrial Invest. Corp. Of Mahrashtra Ltd.
0
27 March 1988
Bank Of India
0
17 March 1992
I.d.b.i.
0
28 August 2000
Icici Limited
0
17 May 1995
Bank Of India
0
17 June 1986
The Skura Bank Ltd.
0
12 June 1986
Bank Of Baroda
0
01 March 1985
The Industrial Credit And Invest. Corp. Of Inida Limited
0
18 November 2002
Cooperative Centrale Raiffeisen Boerenle Enbank B.a.
0
03 February 1982
The State Indutrial & Investment Corp. Of Mahrashtra Ltd.
0
26 December 1977
Bank Of India
0
27 July 1974
Bank Of India
0
18 November 1966
The Bank Of India
0
27 May 1963
Bank Of India
0
18 November 2002
Bank Of India
0
09 October 1989
Bank Of India
0
31 May 2019
Others
0
28 February 2020
Axis Bank Limited
0
04 January 2022
Others
0
16 July 2016
Bank Of India
0
23 January 2018
Citi Bank N.a.
0
01 June 1990
Bank Of Baroda
0
24 May 2000
Birla Sunlife Asset Management Co. Ltd.
0
14 January 2000
Bank Of India
0
15 December 1997
Sicom Limited
0
26 April 1988
The Army Group Insurance Fund
0
27 December 1973
Uttar Pradesh Finacial Corp.
0
03 November 1970
Unichem Laboratories Ltd.
0
27 October 1969
Uttar Pradesh Financial Corp.
0
02 April 1980
The State Indus. Invest. Corp. Of Maharashtra Ltd.
0
23 March 1999
Industrial Development Bank Of Indiat
0
23 February 1999
Bank Of India
0
19 February 1999
Industrial Development Bank Of India
0
18 June 1997
The Sakura Bank Limited
0
07 March 1994
Bank Of Baroda
0
01 October 1991
The Mitsui Taiyo Kobe Bank Ltd.
0
03 July 1991
Bank Of India
0
12 April 1991
The Mitsui Taiyo Kobe Bank Ltd.
0
19 November 2002
Bank Of India
0
13 January 1990
The Mitsui Bank Ltd.
0
27 September 1988
Bank Of India
0
12 May 1980
Bank Of India
0
21 November 1980
Life Insurance Corp. Of India
0
26 December 1986
Bank Of India
0
05 March 1987
Bank Of India
0
31 July 1987
Bank Of India
0
27 August 1988
Bank Of Baroda
0
05 September 1988
Bank Of Baroda
0
15 April 1991
The Industrial Credit And Invest. Corp. Of Inida Limited
0
26 November 2014
Biotechnology Industry Research Assistance Council
0
22 May 1997
Bank Of Baroda
0
13 July 1994
The Sakura Bank Ltd.
0
01 October 1976
The State Industrial Invest. Corp. Of Mahrashtra Ltd.
0
27 March 1988
Bank Of India
0
17 March 1992
I.d.b.i.
0
28 August 2000
Icici Limited
0
17 May 1995
Bank Of India
0
17 June 1986
The Skura Bank Ltd.
0
12 June 1986
Bank Of Baroda
0
01 March 1985
The Industrial Credit And Invest. Corp. Of Inida Limited
0
18 November 2002
Cooperative Centrale Raiffeisen Boerenle Enbank B.a.
0
03 February 1982
The State Indutrial & Investment Corp. Of Mahrashtra Ltd.
0
26 December 1977
Bank Of India
0
27 July 1974
Bank Of India
0
18 November 1966
The Bank Of India
0
27 May 1963
Bank Of India
0
18 November 2002
Bank Of India
0
09 October 1989
Bank Of India
0
31 May 2019
Others
0
28 February 2020
Axis Bank Limited
0
04 January 2022
Others
0
16 July 2016
Bank Of India
0
23 January 2018
Citi Bank N.a.
0
01 June 1990
Bank Of Baroda
0
24 May 2000
Birla Sunlife Asset Management Co. Ltd.
0
14 January 2000
Bank Of India
0
15 December 1997
Sicom Limited
0
26 April 1988
The Army Group Insurance Fund
0
27 December 1973
Uttar Pradesh Finacial Corp.
0
03 November 1970
Unichem Laboratories Ltd.
0
27 October 1969
Uttar Pradesh Financial Corp.
0
02 April 1980
The State Indus. Invest. Corp. Of Maharashtra Ltd.
0
23 March 1999
Industrial Development Bank Of Indiat
0
23 February 1999
Bank Of India
0
19 February 1999
Industrial Development Bank Of India
0
18 June 1997
The Sakura Bank Limited
0
07 March 1994
Bank Of Baroda
0
01 October 1991
The Mitsui Taiyo Kobe Bank Ltd.
0
03 July 1991
Bank Of India
0
12 April 1991
The Mitsui Taiyo Kobe Bank Ltd.
0
19 November 2002
Bank Of India
0
13 January 1990
The Mitsui Bank Ltd.
0
27 September 1988
Bank Of India
0
12 May 1980
Bank Of India
0
21 November 1980
Life Insurance Corp. Of India
0
26 December 1986
Bank Of India
0
05 March 1987
Bank Of India
0
31 July 1987
Bank Of India
0
27 August 1988
Bank Of Baroda
0
05 September 1988
Bank Of Baroda
0
15 April 1991
The Industrial Credit And Invest. Corp. Of Inida Limited
0
26 November 2014
Biotechnology Industry Research Assistance Council
0
22 May 1997
Bank Of Baroda
0
13 July 1994
The Sakura Bank Ltd.
0
01 October 1976
The State Industrial Invest. Corp. Of Mahrashtra Ltd.
0
27 March 1988
Bank Of India
0
17 March 1992
I.d.b.i.
0
28 August 2000
Icici Limited
0
17 May 1995
Bank Of India
0
17 June 1986
The Skura Bank Ltd.
0
12 June 1986
Bank Of Baroda
0
01 March 1985
The Industrial Credit And Invest. Corp. Of Inida Limited
0
18 November 2002
Cooperative Centrale Raiffeisen Boerenle Enbank B.a.
0
03 February 1982
The State Indutrial & Investment Corp. Of Mahrashtra Ltd.
0
26 December 1977
Bank Of India
0
27 July 1974
Bank Of India
0
18 November 1966
The Bank Of India
0
27 May 1963
Bank Of India
0
18 November 2002
Bank Of India
0
09 October 1989
Bank Of India
0
Documents
Form MGT-15-13082024_signed
Form MSME FORM I-24042024_signed
Form Addendum to AOC-4 CSR-11012024_signed
Form MSME FORM I-18102023_signed
Optional Attachment-(2)-26092023
Optional Attachment-(1)-26092023
Copy of MGT-8-26092023
Optional Attachment-(3)-26092023
Shareholders_MGT_7_2023_F65131187_JAYDSOUZA_20230926162705.xlsm
Form MGT-7-26092023_signed
Form MGT-15-25092023_signed
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-25092023
XBRL document in respect Consolidated financial statement-25092023
Form AOC-4(XBRL)-25092023_signed
Form MSME FORM I-30082023_signed
Form MSME FORM I-17042023_signed
Form MSME FORM I-28102022
Form MGT-7-04102022_signed
Optional Attachment-(1)-03102022
Shareholders-MGT_7_F27398247_1234CHOKSHI_20221003181701.xlsm
Copy of MGT-8-03102022
Optional Attachment-(2)-03102022
Form MGT-6-22092022_signed
-22092022
Optional Attachment-(2)-16092022
Optional Attachment-(1)-16092022
Form Addendum to AOC-4 CSR-16092022_signed
XBRL document in respect Consolidated financial statement-05092022
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-05092022
Form AOC-4(XBRL)-05092022_signed
